Equitable Holdings Inc. Takes $785,000 Position in Medpace Holdings, Inc. $MEDP

Posted by Francis Steltz on Aug 30th, 2026

Equitable Holdings Inc. bought a new stake in shares of Medpace Holdings, Inc. (NASDAQ:MEDP – Free Report) in the 2nd quarter, Holdings Channel.com reports. The firm bought 1,482 shares of the company’s stock, valued at approximately $785,000.

A number of other hedge funds have also recently bought and sold shares of MEDP. BOKF NA raised its position in Medpace by 0.8% in the third quarter. BOKF NA now owns 2,542 shares of the company’s stock worth $1,307,000 after acquiring an additional 20 shares in the last quarter. Valeo Financial Advisors LLC lifted its holdings in Medpace by 5.0% in the 4th quarter. Valeo Financial Advisors LLC now owns 444 shares of the company’s stock valued at $249,000 after acquiring an additional 21 shares during the last quarter. UMB Bank n.a. boosted its position in shares of Medpace by 5.6% during the 4th quarter. UMB Bank n.a. now owns 450 shares of the company’s stock valued at $253,000 after purchasing an additional 24 shares in the last quarter. Schulhoff & Co. Inc. boosted its position in shares of Medpace by 1.1% during the 4th quarter. Schulhoff & Co. Inc. now owns 2,202 shares of the company’s stock valued at $1,237,000 after purchasing an additional 25 shares in the last quarter. Finally, Balefire LLC boosted its position in shares of Medpace by 6.1% during the 1st quarter. Balefire LLC now owns 451 shares of the company’s stock valued at $217,000 after purchasing an additional 26 shares in the last quarter. 77.98% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In related news, Director Fred B. Davenport, Jr. sold 7,283 shares of the company’s stock in a transaction on Wednesday, August 19th. The shares were sold at an average price of $606.15, for a total transaction of $4,414,590.45. Following the completion of the sale, the director directly owned 3,798 shares of the company’s stock, valued at approximately $2,302,157.70. This represents a 65.73% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Brian T. Carley sold 5,000 shares of the company’s stock in a transaction dated Wednesday, August 19th. The shares were sold at an average price of $608.63, for a total transaction of $3,043,150.00. Following the sale, the director owned 27,825 shares of the company’s stock, valued at $16,935,129.75. This trade represents a 15.23% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders have sold 133,821 shares of company stock valued at $81,748,135. Insiders own 20.50% of the company’s stock.

Medpace Stock Down 1.8%

Medpace stock opened at $600.65 on Friday. Medpace Holdings, Inc. has a 12 month low of $373.00 and a 12 month high of $677.90. The stock has a market cap of $16.77 billion, a P/E ratio of 35.21, a P/E/G ratio of 2.68 and a beta of 1.15. The company’s fifty day simple moving average is $565.33 and its 200-day simple moving average is $494.55.

Medpace (NASDAQ:MEDP – Get Free Report) last posted its quarterly earnings results on Wednesday, July 22nd. The company reported $4.25 earnings per share for the quarter, topping analysts’ consensus estimates of $3.98 by $0.27. The company had revenue of $707.33 million during the quarter, compared to the consensus estimate of $689.51 million. Medpace had a return on equity of 110.15% and a net margin of 17.67%.The business’s quarterly revenue was up 17.2% on a year-over-year basis. During the same period last year, the business earned $3.10 EPS. Medpace has set its FY 2026 guidance at 17.250-17.950 EPS. On average, equities research analysts expect that Medpace Holdings, Inc. will post 17.54 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of analysts recently commented on MEDP shares. Jefferies Financial Group downgraded shares of Medpace from a “buy” rating to a “hold” rating and boosted their target price for the stock from $490.00 to $515.00 in a report on Tuesday, July 7th. Mizuho raised their target price on shares of Medpace from $586.00 to $665.00 and gave the stock an “outperform” rating in a report on Friday, July 24th. Barclays set a $600.00 price target on shares of Medpace in a research report on Thursday, July 23rd. Leerink Partners set a $620.00 price target on Medpace in a report on Thursday, July 23rd. Finally, BMO Capital Markets upped their price target on Medpace from $400.00 to $600.00 and gave the company a “market perform” rating in a report on Friday, July 24th. Three investment analysts have rated the stock with a Buy rating and ten have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus price target of $584.18.

Check Out Our Latest Report on MEDP

Medpace Profile

(Free Report)

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.